What question did this study set out to answer?

To evaluate the safety and clinical outcomes of extending dosing intervals of teclistamab or talquetamab without repeating step-up dosing in patients with relapsed/refractory multiple myeloma.

August 14, 2026Experimental Hematology and OncologyOpen Access

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

CBCallee Brooks LMLeslie Mader KKKathryn Kennedy

Discussion

Member takes

Overview

Case series demonstrates safe extended-interval teclistamab and talquetamab without repeat step-up dosing in multiple myeloma, suggesting prolonged schedules remain feasible.

Key Points

To evaluate the safety and clinical outcomes of extending dosing intervals of teclistamab or talquetamab without repeating step-up dosing in patients with relapsed/refractory multiple myeloma.
Analyzed a clinical series of N=6 patients with relapsed/refractory multiple myeloma transitioned to extended dosing intervals (8–12 weeks) of teclistamab or talquetamab without step-up dosing re-escalation.
All patients had achieved at least a complete response prior to interval extension, which was initiated to manage late toxicities or maintain deep disease control.
Zero cases of cytokine release syndrome or neurotoxicity occurred across 23 extended-interval doses with a median duration of 77 days between doses, despite initial step-up toxicity rates of 83% for cytokine release syndrome and 17% for neurotoxicity.
All 6 patients maintained sustained, deep treatment responses and remained active on bispecific antibody therapy at the time of reporting.

Cite This Study

Brooks et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec71db70b84ec8b91338d https://doi.org/10.1186/s40164-026-00816-x

View Full Paper

Ask AI

Bookmark

August 14, 2026Experimental Hematology and OncologyOpen Access

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

CBCallee Brooks LMLeslie Mader KKKathryn Kennedy

Discussion

Member takes

Overview

Case series demonstrates safe extended-interval teclistamab and talquetamab without repeat step-up dosing in multiple myeloma, suggesting prolonged schedules remain feasible.

Key Points

To evaluate the safety and clinical outcomes of extending dosing intervals of teclistamab or talquetamab without repeating step-up dosing in patients with relapsed/refractory multiple myeloma.
Analyzed a clinical series of N=6 patients with relapsed/refractory multiple myeloma transitioned to extended dosing intervals (8–12 weeks) of teclistamab or talquetamab without step-up dosing re-escalation.
All patients had achieved at least a complete response prior to interval extension, which was initiated to manage late toxicities or maintain deep disease control.
Zero cases of cytokine release syndrome or neurotoxicity occurred across 23 extended-interval doses with a median duration of 77 days between doses, despite initial step-up toxicity rates of 83% for cytokine release syndrome and 17% for neurotoxicity.
All 6 patients maintained sustained, deep treatment responses and remained active on bispecific antibody therapy at the time of reporting.

Cite This Study

Brooks et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec71db70b84ec8b91338d https://doi.org/10.1186/s40164-026-00816-x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark